Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/59904
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2099-12-31
Coleções
Metadata
Mostrar registro completo
BOOSTER DOSE OF BNT162B2 IN A CORONAVAC PRIMARY VACCINATION PROTOCOL IMPROVES NEUTRALIZATION OF SARS-COV-2 OMICRON VARIANT.
Autor(es)
Campos, Guilherme R F
Almeida, Nathalie Bonatti Franco
Filgueiras, Priscilla Soares
Corsini, Camila Amormino
Gomes, Sarah Vieira Contin
Miranda, Daniel Alvim Pena de
Assis, Jéssica Vieira de
Silva, Thaís Bárbara de Souza
Alves, Pedro Augusto
Fernandes, Gabriel da Rocha
Oliveira, Jaquelline Germano de
Rahal, Paula
Queiroz, Rafaella Fortini Grenfelle
Nogueira, Maurício L
Almeida, Nathalie Bonatti Franco
Filgueiras, Priscilla Soares
Corsini, Camila Amormino
Gomes, Sarah Vieira Contin
Miranda, Daniel Alvim Pena de
Assis, Jéssica Vieira de
Silva, Thaís Bárbara de Souza
Alves, Pedro Augusto
Fernandes, Gabriel da Rocha
Oliveira, Jaquelline Germano de
Rahal, Paula
Queiroz, Rafaella Fortini Grenfelle
Nogueira, Maurício L
Afiliação
Faculdade de Medicina de São José do Rio Preto. Laboratório de Pesquisas em Virologia. São Paulo, SP, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia de Doenças Virais Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia de Doenças Virais Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia Celular e Molecular Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Universidade Estadual Paulista. Instituto de Biociências Letras e Ciências Exatas. Departamento de Biologia. Laboratório de Estudos Genômicos. São José do Rio Preto, SP, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Faculdade de Medicina de São José do Rio Preto. Laboratório de Pesquisas em Virologia. São Paulo, SP, Brazil/Hospital de Base. São José do Rio Preto, SP, State, Brazil/ Department of Pathology. University of Texas Medical Branch. Galveston, TX, USA.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia de Doenças Virais Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia de Doenças Virais Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Laboratório de Imunologia Celular e Molecular Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Universidade Estadual Paulista. Instituto de Biociências Letras e Ciências Exatas. Departamento de Biologia. Laboratório de Estudos Genômicos. São José do Rio Preto, SP, Brazil.
Diagnosis and Therapy of Infectious Diseases and Cancer. Rene Rachou Institure. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Faculdade de Medicina de São José do Rio Preto. Laboratório de Pesquisas em Virologia. São Paulo, SP, Brazil/Hospital de Base. São José do Rio Preto, SP, State, Brazil/ Department of Pathology. University of Texas Medical Branch. Galveston, TX, USA.
Resumo em Inglês
The emergence of the new SARS-CoV-2 Omicron variant, which is known to accumulate a huge number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. In this scenario, we evaluated the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. The percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 17% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times, indicating a positive impact of this vaccine combination in the serological immune response.
Compartilhar